{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:31:44Z","timestamp":1790076704485,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse events. ICI-induced type 1 diabetes mellitus (T1DM) is extremely rare (&lt;\u20091%) but potentially life-threatening. It appears to be more common with PD-1 blockade (or combination immunotherapy) than with anti-CTLA-4 therapy, often during the first three to six months of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Cases presentation<\/jats:title><jats:p>We report an acute onset T1DM with severe inaugural diabetic ketoacidosis (DKA) and remarkably elevated Glutamic Acid Decarboxylase antibody (GADA) titres following a single administration of combined ICI therapy with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in two adult patients with advanced metastatic melanoma. In these cases, the time to diabetes onset was remarkably short (two and five weeks), and one presented with fulminous T1DM in a previous long-standing type 2 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oncological patients treated with combination therapy of anti-PD-1 and anti-CTLA-4 can develop a particular pattern of T1DM, with very rapid onset within a few weeks after starting ICI therapy, even in the presence of an existing type 2 diabetes. ICI-induced T1DM is a medical emergency in presence of severe inaugural DKA and requires a collaboration between specialists and primary care physicians, as well as patient education, for early diagnosis and supportive care.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12902-019-0467-z","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T15:02:39Z","timestamp":1577113359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports"],"prefix":"10.1186","volume":"19","author":[{"given":"Marco","family":"Zezza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Mekoguem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haithem","family":"Chtioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Pitteloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Lamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"issue":"8","key":"467_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"26","key":"467_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"10027","key":"467_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"19","key":"467_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"467_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"2","key":"467_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysisEndocrine dysfunction and immune checkpoint inhibitor RegimensEndocrine dysfunction and immune checkpoint inhibitor regimens. JAMA Oncol. 2018;4(2):173\u201382.","journal-title":"JAMA Oncol"},{"issue":"8","key":"467_CR8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471.","journal-title":"Diabetes."},{"issue":"1","key":"467_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-017-0303-9","volume":"5","author":"PN Changizzadeh","year":"2017","unstructured":"Changizzadeh PN, Mukkamalla SKR, Armenio VA. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. J Immun Cancer. 2017;5(1):97.","journal-title":"J Immun Cancer"},{"key":"467_CR10","first-page":"17","volume":"2018","author":"F Gunawan","year":"2018","unstructured":"Gunawan F, George E, Roberts A. Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinol, Diab Metab Case Rep. 2018;2018:17\u20130146.","journal-title":"Endocrinol, Diab Metab Case Rep"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","volume":"4","author":"JR Lowe","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AKS, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immun Cancer. 2016;4:89.","journal-title":"J Immun Cancer"},{"issue":"9","key":"467_CR12","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"Clotman K, De Block CEM, Janssens K, Specenier P, Weets I. Programmed cell Death-1 inhibitor\u2013induced type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018;103(9):3144\u201354.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"467_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","volume":"66","author":"YK Chae","year":"2017","unstructured":"Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017;66(1):25\u201332.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"467_CR14","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy C, Monestier S, Dubois N, Pr\u00e9au Y, Mallet S, et al. Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes. Diab Care. 2015;38(11):e182.","journal-title":"Diab Care"},{"issue":"6","key":"467_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","volume":"65","author":"E Hansen","year":"2016","unstructured":"Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65(6):765\u20137.","journal-title":"Cancer Immunol Immunother"},{"key":"467_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190\u2013209.","journal-title":"Eur J Cancer"},{"issue":"4","key":"467_CR17","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diab Care. 2015;38(4):e55\u2013e7.","journal-title":"Diab Care"},{"issue":"6","key":"467_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64(6):765\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"467_CR19","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0889","volume":"38","author":"M Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, et al. Anti\u2013PD-1 and anti\u2013PDL-1 monoclonal antibodies causing type 1 diabetes. Diab Care. 2015;38(9):e137.","journal-title":"Diab Care"},{"issue":"2","key":"467_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1620\/tjem.239.155","volume":"239","author":"Y Miyoshi","year":"2016","unstructured":"Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell Death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med. 2016;239(2):155\u20138.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"467_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","volume":"105","author":"W Munakata","year":"2017","unstructured":"Munakata W, Ohashi K, Yamauchi N, Tobinai K. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. 2017;105(3):383\u20136.","journal-title":"Int J Hematol"},{"issue":"6","key":"467_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diab Invest. 2016;7(6):915\u20138.","journal-title":"J Diab Invest"},{"issue":"5","key":"467_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/1346-8138.13486","volume":"44","author":"Y Teramoto","year":"2017","unstructured":"Teramoto Y, Nakamura Y, Asami Y, Imamura T, Takahira S, Nemoto M, et al. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol. 2017;44(5):605\u20136.","journal-title":"J Dermatol"},{"key":"467_CR24","doi-asserted-by":"crossref","unstructured":"Aleksova J, Lau PKH, Soldatos G, McArthur G. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep. 2016;2016:bcr2016217454.","DOI":"10.1136\/bcr-2016-217454"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","volume":"5","author":"JL Godwin","year":"2017","unstructured":"Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immun Cancer. 2017;5:40.","journal-title":"J Immun Cancer"},{"issue":"26","key":"467_CR26","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced Cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"467_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1159\/000480634","volume":"10","author":"J Kapke","year":"2017","unstructured":"Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management. Case Rep Oncol. 2017;10(3):897\u2013909.","journal-title":"Case Rep Oncol"},{"issue":"4","key":"467_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883.","journal-title":"J Exp Med"},{"issue":"33","key":"467_CR29","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A. 2005;102(33):11823\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"467_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJI Ansari","year":"2003","unstructured":"Ansari MJI, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed Death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198(1):63.","journal-title":"J Exp Med"},{"key":"467_CR31","doi-asserted-by":"crossref","unstructured":"de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019.","DOI":"10.1530\/EJE-19-0291"},{"issue":"2","key":"467_CR32","first-page":"49","volume":"169","author":"A Alzenaidi","year":"2017","unstructured":"Alzenaidi A, Dendy J, Rejjal L. Autoimmune Diabetes Presented with Diabetic Ketoacidosis Induced by Immunotherapy in an Adult with Melanoma. J La State Med Soc: Official Organ La State Med Soc. 2017;169(2):49.","journal-title":"J La State Med Soc: Official Organ La State Med Soc"},{"issue":"Suppl 1","key":"467_CR33","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc19-S002","volume":"42","author":"DA American","year":"2019","unstructured":"American DA. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2019. Diab Care. 2019;42(Suppl 1):S13\u201328.","journal-title":"Diab Care"},{"issue":"11","key":"467_CR34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"M-L Gauci","year":"2017","unstructured":"Gauci M-L, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, et al. Autoimmune diabetes induced by PD-1 inhibitor\u2014retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother. 2017;66(11):1399\u2013410.","journal-title":"Cancer Immunol Immunother"},{"key":"467_CR35","doi-asserted-by":"crossref","unstructured":"Saito D, Oikawa Y, Mizutani G, Inoue K, Hatano M, Inoue I, et al. Clinical characteristics of anti-glutamic acid decarboxylase antibody-positive fulminant type 1 diabetes. Endocr J. 2019;advpub.","DOI":"10.1507\/endocrj.EJ18-0417"},{"issue":"17","key":"467_CR36","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol : Official J Am Soc Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol : Official J Am Soc Clin Oncol"},{"issue":"2","key":"467_CR37","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2018","unstructured":"Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, et al. French Endocrine Society guidance on endocrine side-effects of immunotherapy. Endocr Relat Cancer. 2018;26(2):G1\u2013G18.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"467_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","volume":"10","author":"MY Baden","year":"2019","unstructured":"Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019;10(1):58\u201366.","journal-title":"Diabetol Int"},{"issue":"4","key":"467_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","volume":"56","author":"L Marchand","year":"2019","unstructured":"Marchand L, Thivolet A, Dalle S, Chikh K, Reffet S, Vouillarmet J, et al. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol. 2019;56(4):441\u20138.","journal-title":"Acta Diabetol"},{"issue":"Suppl 1","key":"467_CR40","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.2337\/dc19-S006","volume":"42","author":"DA American","year":"2019","unstructured":"American DA. 6. Glycemic targets: standards of medical Care in Diabetes-2019. Diab Care. 2019;42(Suppl 1):S61\u201370.","journal-title":"Diab Care"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0467-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T07:26:30Z","timestamp":1665300390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0467-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0467-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval: Not applicable.Consent for publication: A written informed consent was obtained from the patient 1 and from next of kin for patient 2 for the publication of the case report. A copy of the written consent is available for review by the Editors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}